Merck & Co. Inc., Kenilworth, NJ 07033, USA.
Future Oncol. 2021 Feb;17(4):423-433. doi: 10.2217/fon-2020-0728. Epub 2020 Nov 17.
We evaluated the relationship between clinical and genomic characteristics and tumor mutational burden (TMB) in small cell lung cancer. In a retrospective analysis of small cell lung cancer patients aged ≥18, we assessed treatment patterns and survival in relation to TMB; the association of clinical and genomic characteristics with TMB was determined by multivariate regression. High TMB (TMB-H) was defined as ≥10 mutations/megabase. Among 186 patients, treatment patterns and overall survival were similar for TMB-H and non-TMB-H patients. TMB was determined for 179 patients, 41.9% of whom were TMB-H. Short variants of and were significantly associated with TMB-H (p ≤ 0.01). Neither treatment patterns nor survival differed by TMB status.
我们评估了小细胞肺癌的临床和基因组特征与肿瘤突变负担（TMB）之间的关系。在一项对≥18 岁小细胞肺癌患者的回顾性分析中，我们评估了 TMB 与治疗模式和生存的关系；通过多变量回归确定了临床和基因组特征与 TMB 的关联。高 TMB（TMB-H）定义为≥10 个突变/兆碱基。在 186 名患者中，TMB-H 和非 TMB-H 患者的治疗模式和总生存率相似。对 179 名患者进行了 TMB 检测，其中 41.9%为 TMB-H。和 的短变体与 TMB-H 显著相关（p≤0.01）。TMB 状态与治疗模式或生存均无差异。
